The European Society of Cardiology reports a correction in the article by Ponikowski et al. entitled, “2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure”, whose Spanish translation was published in Rev Esp Cardiol. 2016;69:1167.e1-e85.
In section 11.6, in paragraph 5, the sentence: ‘Dipeptidylpeptidase-4 inhibitors (DPP4is; gliptins), which increase incretin secretion, thereby stimulating insulin release, and longacting glucagon-like peptide 1 (GLP-1) receptor agonists, which act as incretin mimetics, improve glycaemic indices but do not reduce and may increase the risk of cardiovascular events and worsening HF.’ was amended to: ‘Dipeptidylpeptidase-4 inhibitors (DPP4is; gliptins), which increase incretin levels by reducing its degradation, thereby stimulating insulin release, and longacting glucagon-like peptide 1 (GLP-1) receptor agonists, which act as incretin mimetics, improve glycaemic indices but do not reduce and may increase the risk of cardiovascular events and worsening HF.’
The paper has now been corrected online.